Condition 1: Gynecological cancer. Condition 2: Urological Cancer. Malignant neoplasm of female genital organ, unspecified Malignant neoplasm of bladder, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Patients are treated with atorvastatin at a dose of 40 mg daily from the beginning of radiotherapy to 3 months after treatment. Intervention 2: Control group: Patie
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Pelvic radiotherapy indication due to gynecological, urological and lower gastrointestinal cancers. At least 18 years old. The total pelvic dose of patients during radiotherapy should be between 45-50 Gy. Acceptable renal function and GFR> 60 Satisfaction to participate in the study
Exclusion criteria
Exclusion criteria: Having a history of pelvic radiotherapy. Having diabetes due to the possibility of intestinal disorders Having an active liver or muscle disease Having the contraindications to the use of statins Having a serious physical or mental problem that prevents the completion of the course of treatment Evidence of metastasis (having a performance status score greater than 70) Taking cytochrome P450 3A4 inhibitors Unwillingness to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastrointestinal toxicity. Timepoint: Before the intervention, during the intervention, immediately after the intervention, three months after the intervention. Method of measurement: Inflammatory Bowel Disease questionnaire-bowel(IBDQ-B). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSimin Hemati
Esfahan University of Medical Sciences
Outcome results
None listed